3-HO-PCE: Difference between revisions

Line 11:

There is a complete lack of data on the pharmacological properties, metabolism, and toxicity of 3-HO-PCE, and it has an extremely brief history of human usage. It is exclusively distributed as a gray area [[research chemical]] by online vendors.<ref name="PCP2MXE /> Due to its potential habit-forming properties, and unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.

==History and culture==

On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, which includes 3-HO-PCE.<ref> "[https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119087/methoxetamine2012.pdf (ACMD) Methoxetamine Report (2012)]" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2015-06-24.</ref>

==Chemistry==

@@ Line 11: / Line 11: @@
 There is a complete lack of data on the pharmacological properties, metabolism, and toxicity of 3-HO-PCE, and it has an extremely brief history of human usage. It is exclusively distributed as a gray area [[research chemical]] by online vendors.<ref name="PCP2MXE /> Due to its potential habit-forming properties, and unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.
+==History and culture==
+{{historyStub}}
+On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, which includes 3-HO-PCE.<ref> "[https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119087/methoxetamine2012.pdf (ACMD) Methoxetamine Report (2012)]" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2015-06-24.</ref>
 ==Chemistry==